Palisade bio (nasdaq: pali) announces analysis demonstrating lb1148 reduced the extent and severity of post-surgical intraabdominal adhesions by 93%

Data from pooled-analysis of enteral protease inhibitor lb1148 demonstrated 72% reduction in the risk of adhesion formation in patients undergoing bowel resection surgery

PALI Ratings Summary

PALI Quant Ranking